Cargando…

The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma

BACKGROUND: Nasal NK/T cell lymphoma is an aggressive disease and has a poor prognosis. Nasal NK/T cell lymphoma is refractory to conventional chemotherapy and has strong tendency of widespread relapse or dissemination into distant sites. METHODS: We immunohistochemically studied nasal NK/T-cell lym...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakata, Koh-ichi, Someya, Masanori, Omatsu, Mutsuko, Asanuma, Hiroko, Hasegawa, Tadashi, Hareyama, Masato, Himi, Tetsuo
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2238761/
https://www.ncbi.nlm.nih.gov/pubmed/18093334
http://dx.doi.org/10.1186/1471-2407-7-229
_version_ 1782150458381434880
author Sakata, Koh-ichi
Someya, Masanori
Omatsu, Mutsuko
Asanuma, Hiroko
Hasegawa, Tadashi
Hareyama, Masato
Himi, Tetsuo
author_facet Sakata, Koh-ichi
Someya, Masanori
Omatsu, Mutsuko
Asanuma, Hiroko
Hasegawa, Tadashi
Hareyama, Masato
Himi, Tetsuo
author_sort Sakata, Koh-ichi
collection PubMed
description BACKGROUND: Nasal NK/T cell lymphoma is an aggressive disease and has a poor prognosis. Nasal NK/T cell lymphoma is refractory to conventional chemotherapy and has strong tendency of widespread relapse or dissemination into distant sites. METHODS: We immunohistochemically studied nasal NK/T-cell lymphoma to elucidate the unique characteristics of nasal NK/T-cell lymphoma, such as its higher metastatic tendency and its vast necrosis which leads to destruction of the involved tissues. The expression of P-glycoprotein and MMP-9 was evaluated in the 20 patients with nasal NK/T-cell lymphoma and 25 with nasal non-NK/T-cell lymphoma and the relationship between expression of these proteins and clinical results were analyzed in this report. RESULTS: Overall 5-year survival rates for patients with nasal NK/T cell lymphoma, and nasal non-NK/T cell lymphoma were 51%, and 84%. Distant involvement free 5-year survival rates for patients with nasal NK/T cell lymphoma, and nasal non-NK/T cell lymphoma were 53%, and 79%. Overall positivity for P-glycoprotein was observed in 10 of 19 patients with NTL and in 13 of 23 patients with non-NTL. When the overall survival rate was compared between patients with P-glycoprotein positive and negative, there was no difference between them. Sixteen of the 19 patients with nasal NK/T cell lymphoma expressed MMP-9. In contrast, only 8 of the 22 patients with nasal non-NK/T cell lymphoma expressed MMP-9. Distant involvement free 5-year survival rates for patients with MMP-9 negative, and MMP-9 positive were 92%, and 61%, respectively. The difference was statistically significant (p = 0.027). CONCLUSION: Positive immunoreactivity for P-glycoprotein was not an independent prognostic factor in nasal NK/T-cell lymphomas, which stresses the importance of exploring other mechanisms of drug resistance. The strong expression of MMP-9 is uniquely characteristic of nasal NK/T cell lymphoma and may contribute to its strong tendency to disseminatate and the extensive necrosis which is always seen. However, our results are based on univariate comparisons, and as such, should be viewed with some caution.
format Text
id pubmed-2238761
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22387612008-02-12 The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma Sakata, Koh-ichi Someya, Masanori Omatsu, Mutsuko Asanuma, Hiroko Hasegawa, Tadashi Hareyama, Masato Himi, Tetsuo BMC Cancer Research Article BACKGROUND: Nasal NK/T cell lymphoma is an aggressive disease and has a poor prognosis. Nasal NK/T cell lymphoma is refractory to conventional chemotherapy and has strong tendency of widespread relapse or dissemination into distant sites. METHODS: We immunohistochemically studied nasal NK/T-cell lymphoma to elucidate the unique characteristics of nasal NK/T-cell lymphoma, such as its higher metastatic tendency and its vast necrosis which leads to destruction of the involved tissues. The expression of P-glycoprotein and MMP-9 was evaluated in the 20 patients with nasal NK/T-cell lymphoma and 25 with nasal non-NK/T-cell lymphoma and the relationship between expression of these proteins and clinical results were analyzed in this report. RESULTS: Overall 5-year survival rates for patients with nasal NK/T cell lymphoma, and nasal non-NK/T cell lymphoma were 51%, and 84%. Distant involvement free 5-year survival rates for patients with nasal NK/T cell lymphoma, and nasal non-NK/T cell lymphoma were 53%, and 79%. Overall positivity for P-glycoprotein was observed in 10 of 19 patients with NTL and in 13 of 23 patients with non-NTL. When the overall survival rate was compared between patients with P-glycoprotein positive and negative, there was no difference between them. Sixteen of the 19 patients with nasal NK/T cell lymphoma expressed MMP-9. In contrast, only 8 of the 22 patients with nasal non-NK/T cell lymphoma expressed MMP-9. Distant involvement free 5-year survival rates for patients with MMP-9 negative, and MMP-9 positive were 92%, and 61%, respectively. The difference was statistically significant (p = 0.027). CONCLUSION: Positive immunoreactivity for P-glycoprotein was not an independent prognostic factor in nasal NK/T-cell lymphomas, which stresses the importance of exploring other mechanisms of drug resistance. The strong expression of MMP-9 is uniquely characteristic of nasal NK/T cell lymphoma and may contribute to its strong tendency to disseminatate and the extensive necrosis which is always seen. However, our results are based on univariate comparisons, and as such, should be viewed with some caution. BioMed Central 2007-12-19 /pmc/articles/PMC2238761/ /pubmed/18093334 http://dx.doi.org/10.1186/1471-2407-7-229 Text en Copyright © 2007 Sakata et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sakata, Koh-ichi
Someya, Masanori
Omatsu, Mutsuko
Asanuma, Hiroko
Hasegawa, Tadashi
Hareyama, Masato
Himi, Tetsuo
The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma
title The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma
title_full The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma
title_fullStr The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma
title_full_unstemmed The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma
title_short The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma
title_sort enhanced expression of the matrix metalloproteinase 9 in nasal nk/t-cell lymphoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2238761/
https://www.ncbi.nlm.nih.gov/pubmed/18093334
http://dx.doi.org/10.1186/1471-2407-7-229
work_keys_str_mv AT sakatakohichi theenhancedexpressionofthematrixmetalloproteinase9innasalnktcelllymphoma
AT someyamasanori theenhancedexpressionofthematrixmetalloproteinase9innasalnktcelllymphoma
AT omatsumutsuko theenhancedexpressionofthematrixmetalloproteinase9innasalnktcelllymphoma
AT asanumahiroko theenhancedexpressionofthematrixmetalloproteinase9innasalnktcelllymphoma
AT hasegawatadashi theenhancedexpressionofthematrixmetalloproteinase9innasalnktcelllymphoma
AT hareyamamasato theenhancedexpressionofthematrixmetalloproteinase9innasalnktcelllymphoma
AT himitetsuo theenhancedexpressionofthematrixmetalloproteinase9innasalnktcelllymphoma
AT sakatakohichi enhancedexpressionofthematrixmetalloproteinase9innasalnktcelllymphoma
AT someyamasanori enhancedexpressionofthematrixmetalloproteinase9innasalnktcelllymphoma
AT omatsumutsuko enhancedexpressionofthematrixmetalloproteinase9innasalnktcelllymphoma
AT asanumahiroko enhancedexpressionofthematrixmetalloproteinase9innasalnktcelllymphoma
AT hasegawatadashi enhancedexpressionofthematrixmetalloproteinase9innasalnktcelllymphoma
AT hareyamamasato enhancedexpressionofthematrixmetalloproteinase9innasalnktcelllymphoma
AT himitetsuo enhancedexpressionofthematrixmetalloproteinase9innasalnktcelllymphoma